The recall was initiated because a visual inspection confirmed the possibility of particulate contamination which is not acceptable for an intravenous use preparation.
The recall is for the following batches only:
108AB Expiry 12/01/2023113H Expiry 16/03/2023
Ceva Animal Health Ltd is contacting veterinary surgeons, retailers and wholesale dealers to examine inventory and quarantine products subject to the recall.
For further information, contact Peter Kyte Business Unit Manager on +44 1494 781510.
The study, titled “Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010 – 2019)”, also suggests that a urine protein: creatinine greater than 0.5 should prompt reassessment within one week.
For the study, the clinical records of 38 dogs referred to a single university teaching hospital between 2010 and 2019 for treatment of neoplasia with masitinib were retrospectively evaluated.
Data was collected at masitinib initiation and at various timepoints following the start of treatment.
Data gathered included the masitinib dose given and any changes to medication administration or dosing since the previous visit, presence of gross disease and the results of haematology and biochemistry profiles, urinalysis and urine cultures.
Urinalysis results were only included if they were performed at a reference laboratory.
At each timepoint, the urine was classified as non-proteinuric (UP:C ≤0.5) or proteinurinc (UP:C >0.5). Proteinuria was then categorised as likely pre-renal, post-renal, physiological renal or pathological renal.
Dogs were grouped based on the presence or absence of proteinuria at baseline. Non-proteinuric dogs were further divided, based on whether proteinuria developed following treatment during the study.
Of the 28 dogs in the study, five were being treated for epitheliotropic lymphoma, one for vulval lymphoma, one for malignant melanoma and 21 for mast cell tumours.
Twenty-two (79%) dogs were non-proteinuric and six were proteinuric at baseline.
Of the dogs that were non-proteinuric at baseline, four (18.2%) developed proteinuria within one month of treatment initiation. Median time to first detection of proteinuria was 14.5 days (range: 13 to 31).
Of the dogs with pre-treatment proteinuria (n=6), masitinib treatment was discontinued due to lack of efficacy in three dogs, and three were euthanased during treatment, two for disease progression and one for an unknown reason.
Dr Margaux Kuijlaars, corresponding author for the paper, said: “Patients developing proteinuria should be investigated to exclude non-renal causes. This should allow for more informed recommendations on the monitoring and management of proteinuria and further masitinib treatment in these patients to be made. Masitinib treatment can be considered in patients with pre-treatment proteinuria and does not inevitably cause worsening of proteinuria.
“The findings of this study add to the evidence base for the use of masitinib in treating neoplasia in small animal patients. The use of masitinib in dogs in this study was off-licence as C-KIT MCT expression was not determined, and many dogs were treated for other tumours.”
Nicola Di Girolamo, Editor of JSAP, said: “Little is known about which dogs are predisposed to becoming proteinuric following treatment with masitinib for neoplasia. Due to the small number of dogs in this study that developed proteinuria, conclusions about predisposing factors cannot be definitely drawn.
"The findings of this study add to the evidence base and demonstrate the need for larger, prospective trials including a control population and longer period of follow-up.”
The full article can be found in the August issue of the Journal of Small Animal Practice and can be read online here: https://www.onlinelibrary.wiley.com/doi/10.1111/jsap.13305. It is open access and can be freely accessed by anyone.
Reference
Tim was the principal veterinary surgeon at Nine Mile Veterinary Group in Wokingham, Berkshire, from its opening in 1985. He grew the business from one vet and three staff to 16 vets and 60 staff, before selling to CVS in 2007.
Thereupon he became the National Veterinary Director for CVS, supporting the business as it grew from 200 to 1200 vets and supporting individual vets and practices with management advice and clinical practice.
In more recent times Tim has been working with a peripatetic surgery group.
Tim has worked at Guide Dogs before: between 1987 and 2007, he was a Centre Veterinary Advisor at the charity’s now-closed site in Wokingham.
Tim said: “Guide dogs are fantastic to work with – they are good-natured and easy to handle, and the owners always have the best interests of the dog at heart. Plus, you know you are helping more than someone’s pet, a working dog making a real difference to a person’s life. A guide dog needs to be happy and healthy to fulfil its role. It all adds up to a very different flavour of vet work.
“I am looking forward to being back, but in a more central role with more strategic responsibility. The veterinary world has changed so much, even in the last ten years, and it will be good to draw on my experiences to help Guide Dogs traverse that change.
“It’s important that we keep the healthcare of guide dogs at the top of the priorities list; the dogs have always been at the very core of the charity. It’s crucial that we have solid relationships with veterinary practices, to ensure our dogs receive the greatest care at the best value to the charity."
The company initiated the recall after identifying a potential for the sterility/stability of the product to be compromised due to a crimping problem of the aluminium cap.
The recall is for the 100 ml bottles of the following batch only:
Batch No.0C3829 Expiry Date 03/12/2022
Vetoquinol UK Ltd is contacting veterinary surgeons and veterinary wholesalers to examine inventory immediately and quarantine products subject to this recall.
For further information, contact the Customer Services Department on +44 1280 814500 Option 1 or email: UK_office@vetoquinol.com.
The report also revealed the devastating impact on overworked veterinary staff, with some left in tears by abusive owners venting their frustration at being unable to find care for their animal.
Anecdotally, the problems highlighted by ITV News are being seen elsewhere in the country, with more and more vets now starting to question whether or not the current requirement to provide out of hours care is sustainable in a world where there are more clients who increasingly expect flea treatment advice and other non emergency situations to be dealt with at 3:00am in the morning.
Various solutions have been proposed in a forum discussion on VetSurgeon.org, including the removal of the requirement to provide an OOH service, for the RCVS to give vets the confidence to say no to non emergencies, a change to the CoPC to require vets to provide emergency care within 24 hours, not 24 hours a day, a requirement for new grads to undertake OOH as part of their PDP, and/or a requirement for OOH centres to have 3 vets on duty at any one time (which could improve working conditions).
As the ITV report pointed out, the fundamental issue is one of a shortage of supply over demand, for which there is no overnight fix. However, many feel that reducing the demands of providing OOH could ease the situation considerably.
IVC says the new brand will allow better communication for equine teams within the IVC Evidensia group as well as collaboration with the wider equine world.
IVC Evidensia Equine Vets range from graduates to European Specialists, working in both dedicated equine and mixed practice, with all practices supported by the four large equine veterinary referral hospitals in the UK: Donnington Grove Veterinary Group, Fyrnwy Equine Group, Oakham Veterinary Hospital and Pool House Equine.
IVC says the brand's mission is to put the welfare of horses at the heart of everything it does, to providing outstanding continuity of care for all equine species and breeds across the network, to be at the forefront of continual professional development, supporting and facilitating the development of clinical and leadership skills across all their equine teams, and to build the leading network for equine veterinary care across Europe.
Richard Stephenson, Chair of the IVC Evidensia Equine Clinical Board, said: "Our network brings together all forms of equine work from ambulatory practice to some of leading UK equine referral centres.
“It gives support to all our staff in their careers. We facilitate clinical development from the graduate academy, through intern training, residencies and training up to European Diplomat level.
“We provide coaching and leadership, flexible roles and friendly, inclusive teams.”
For more information, visit https://www.ivcevidensia.co.uk/Equine or stand B01 at BEVA 2021 congress.
The RCVS Disciplinary Committee has restored a veterinary surgeon who had previously been convicted of fraud to the Register, after finding him fit to resume practising.
Matthew Morgan had pleaded guilty to four counts of fraud in July 2013 having fraudulently claimed over £200,000 in pet insurance claims between November 2009 and December 2012. In August 2013 he was sentenced to two years’ imprisonment, for which he served 12 months and was then released on licence.
Following his conviction and sentence, his case was brought to the RCVS Disciplinary Committee in February 2014 where it was decided to strike him off the Register. When his licence period expired on 18 August 2015, Mr Morgan applied for restoration to the Register.
During the course of the hearing, the Disciplinary Committee heard evidence from Mr Morgan, who accepted the findings of the Committee, describing the evidence as ‘fair’ and acknowledging the seriousness of his actions.
The Committee felt that Mr Morgan’s criminal conduct was very grave, as reflected in his custodial sentence and the fact that, as an Australian citizen, he had been issued with a deportation notice by the Home Office. It also felt that his crime had struck at the heart of public confidence in a profession for which honesty and integrity is expected.
However, the Committee considered that Mr Morgan, if restored, would pose few risks in respect of protection of the public, having no concerns about his competence as a veterinary surgeon, and accepted that there was little future risk to animal welfare if he were to be restored.
The Committee also considered that, since his release from prison, Mr Morgan has taken extensive steps to rehabilitate himself, has undertaken continuing professional development and has been working as a veterinary care assistant at two veterinary practices to keep up-to-date with current practice.
Furthermore, the Committee was satisfied that there was public support for Mr Morgan continuing as a veterinary surgeon given the references and testimonials submitted on his behalf.
In coming to its conclusion the Disciplinary Committee reiterated the seriousness of Mr Morgan’s criminal offending, saying that it had caused it “the greatest concern”. However, it also felt that issues of rehabilitation needed to be considered.
Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: “The Committee cannot emphasise enough the fact that veterinary surgeons who commit acts of fraud in the exercise of their practice can expect severe consequences, both in the criminal courts and within their own College and there can be no doubt that the decision to remove the applicant from the Register was a proper reflection of the seriousness of his offending.
“Given all of the matters referred to above, however, the Committee considers that the applicant has demonstrated sufficiently that he has learned the lessons required and is now fit to be restored to the Register.”
Elanco Animal Health has announced the launch of Osurnia, a new treatment which it says will drive compliance when treating canine otitis externa infections.
According to the company, compliance with daily ear drops has been shown to be poor, with up to 80% of owners administering the incorrect dose to their pet. The most common reason for a lack of compliance is the difficultly in applying the drops1.
Elanco says that Osurnia has the potential to improve compliance in treating otitis externa significantly, because unlike other medications which require 5-28 doses during the course of treatment2, Osurnia only needs two-doses given a week apart.
Osurnia contains a gel formulation of three active ingredients including the antibiotic florfenicol, which is new to companion animal treatment in the UK, terbinafine, which inhibits the growth of yeast as demonstrated for Malassezia spp., and the glucocorticosteroid, betamethasone acetate, to help relieve discomfort.
Osurnia is administered in a pre-measured, single-dose tube designed to ensure the right dose every time. It has a flexible, soft tip designed to make treatment with Osurnia a comfortable experience for the dog. The gel formulation squeezes out of the tube and spreads through the ear, adhering inside the ear canal for long-lasting action. The dose is the same for any dog, regardless of size and weight.
Alice Laurens, DVM MRCVS, dermatology marketing manager at Elanco Animal Health said: “Otitis externa is a common challenge for both vets and clients, with ear infections among the ten most frequent reasons for dogs to be presented with vets, affecting up to 20% of dogs3.
“Osurnia is an innovative, effective treatment that is administered in just two doses ensuring it is much more convenient for pet owners thereby increasing the likelihood that they will complete the entire treatment schedule leading to more comfortable dogs and peace of mind for owners.”
Elanco has produced a client leaflet on treating otitis externa with Osurnia. For further information, or to order client leaflets, please contact your local Elanco Animal Health Territory Manager or email elancoCAH.uk@elanco.com.
References
Willows, the Solihull-based multidisciplinary referral centre, has announced that it has acquired The Veterinary Cardiorespiratory Centre, the renowned referral service run by Mike Martin MRCVS, RCVS Specialist in Veterinary Cardiology (pictured right).
Mike, together with Chris Linney and their team will shortly be moving half-an-hour up the road to join the team at Willows.
The company says that the move will offer a number of benefits to referring practitioners. Chief amongst these is the speed with which an accurate diagnosis can be made and treatment given, both as a result of having RCVS Specialists in neurology, imaging, medicine, soft tissue surgery (and now cardiology) under one roof and because of the state-of-the-art equipment at their disposal, including CT, MRI and digital fluoroscopy.
Lynne Hill, CEO, Willows Group said: ”I’m thrilled that Mike, Chris and their team are joining us at Willows. I have always held Mike in the highest regard and this is a tremendous opportunity for the practice to provide a truly collaborative ‘one-stop-shop’ for both clients and referring veterinary practices”.
Mike said: “I’m really looking forward to working at Willows Referral Service and being part of a multidisciplinary team. It's a logical move to provide Willows with the missing discipline of cardiology and I'm delighted Lynne Hill has allowed us to fulfil that role. There has been an increasing number of referrals between the two centres due to the complexity of cases - now that will be all under one roof and we can manage these much more effectively and offer the best service to our clients and their patients.”
For more information, visit www.willows.uk.net
Virbac has launched Cooldent, described as a highly palatable, fast-acting tablet to freshen dogs' breath.
Claire Lewis, Product Manager, explained: "Bad breath in dogs is unpleasant and is most frequently caused by a build-up of plaque and calculus on their teeth.
"Cooldent's natural ingredients have an anti-plaque action and help both to maintain a balanced intestinal flora and to reduce gas production. They also help to freshen dogs’ mouths by contributing to the reduction of volatile compounds, produced by bacteria which can cause halitosis."
She added: "We are delighted to add Cooldent to our comprehensive dental range, alongside our VeggieDent, natural, all-vegetable, highly palatable teeth-cleaning chews for dogs and Vet Aquadent, an easy-to-use drinking water additive which helps to fight dental plaque and tartar formation in dogs and cats."
Zoetis has announced that PropoFlo Plus is now back in stock following a huge surge in demand caused by supply issues with a competitor propofol.
Licensed for use in dogs and cats, PropoFlo Plus is an anaesthetic injection for the induction and maintenance of general anaesthesia for up to 20 minutes. It is used for dental treatment, biopsies, radiographs, mass removals and endoscopy.
Ned Flaxman, companion animal business unit director at Zoetis said: “Following an unprecedented demand for PropoFlo Plus, which we believe was caused by an out of stock situation from a competitor product, we have quickly ramped up production in order to return PropoFlo Plus to the market as quickly as possible. I am pleased to confirm that we now have sufficient stocks to supply the entire UK veterinary market for the foreseeable future”.
For further information, contact your Zoetis Account Manager.
Ceva Animal Health has launched Hepaticare, a new liver support supplement for cats and dogs.
The company says Hepaticare contains the same high quality ingredients as Hepatosyl, but is now enhanced with micro-encapsulated SAMe to enhance product stability and patient acceptance.
Hepaticare contains the antioxidants of S-adenosylmethionine (SAMe), vitamin E and silybin to help maintain liver function, and vitamin K to support the normal blood clotting process. Ceva says these ingredients help neutralise damaging free radicals produced by the liver during times of stress, while the SAMe has been micro-encapsulated to enhance stability, reduce any bitter aftertaste and increase patient acceptance.
Hepaticare capsules can be given whole or opened and sprinkled onto, or mixed with, food.
Rob McLintock, companion animal business unit manager at Ceva Animal Health, said: “Following a change in supplier we have taken the opportunity to launch a new liver support supplement, ensuring that the new and improved product, Hepaticare, is as effective and as easy to administer as possible.”
Hepaticare pack sizes and pricing will remain the same as for Ceva’s Hepatosyl. Until the end of September, Hepaticare will be available on a buy one get one free offer.
For further information, contact your local Ceva territory manager or phone 01494 781510.
CarefreeCredit, the loan company set up by Somerset vet Stewart Halperin so that practices can offer their clients interest free loans to cover emergency veterinary treatment, has embarked on a national PR campaign to raise awareness amongst pet owners about the service.
First out of the stalls was the Sunday Express, which covered the story last weekend. Further coverage is expected in other national newspapers over the coming few weeks.
CarefreeCredit provides loans from £250 to £25,000 for use against any veterinary bills. Credit terms offered by CarefreeCredit-enrolled veterinary practices, of which there are now more than 700, are normally 0% over 12 months or 9.9% over 24 months.
Practices pay £10 per month to enrol with CarefreeCredit, plus a small percentage of the amount of each loan made.
Stewart said: “Most vets usually end up discounting their invoices to enable pets to receive the treatment they desperately need when their owners aren’t insured and can’t afford to pay a large bill all at once. With CarefreeCredit, the owner doesn’t have to worry about paying the bill, the pet gets the treatment it needs and the vet is paid immediately and doesn’t have to worry about bad debts. Experience with this type of finance in the US shows that the average vet can reduce his debtors by up to 60%, improving his cash flow, while increasing his turnover by up to 22% per annum, so everyone’s a winner!”
For further information about offering CarefreeCredit to your clients, visit: http://www.carefreecredit.co.uk.
With Vetscan Imagyst, samples are prepared in-clinic using traditional methods, but submitted digitally, rather than sending physical slides to a laboratory. In this way, results are available in hours, allowing vets to offer same-day diagnosis and treatment.
The company says the new digital cytology application offers fast, accurate reviews of common cytology specimens, such as fine-needle aspirates,
Jamie Brannan, President International Operations, Zoetis said: "Veterinarians have told us that Vetscan Imagyst technology helps them make better informed decisions in a more transparent way for pet owners. With the cytology feature, Vetscan Imagyst will now offer one platform for multiple tests.”
He added: “We are excited to build on the incredible momentum that began with the AI fecal analysis launch. Vetscan Imagyst has been a significant part of the Zoetis portfolio and continues to evolve to meet diagnostic needs in practices around the world. The unique all-in-one technology has added immense value to veterinary clinics, facilitating fast, more accurate results, leading to quicker diagnoses and decisions that ultimately strengthen the bond of trust between veterinarians and their clients.”
For more information, contact your Zoetis representative or visit www.vetscanimagyst.com
For the study, researchers reviewed more than three million medical records from Banfield Pet Hospital across 60 breeds of dogs in the United States, finding that periodontal disease (both gingivitis and periodontitis) occurred in 18.2% of dogs overall (517,113 cases).
The authors say that while the true prevalence of periodontal disease (44-100% of cases) is only realised through in-depth clinical investigation, the figure reported in this study was consistent with other research based on conscious oral examinations.
When the authors reviewed the data by dog size, they found that extra-small breeds (<6.5 kg/14.3 lbs) were up to five times more likely to be diagnosed with periodontal disease than giant breeds (>25 kg/55 lbs)(P <0.0001).
Additional risk factors for periodontal disease seen in the study included a dog’s age, being overweight and time since last scale and polish.
Dr Corrin Wallis, Microbiome Workstream Leader at the Waltham Petcare Science Institute said: "This is not the first study suggesting that smaller dogs are more likely to have dental problems than larger dogs, but many of the earlier studies looked at a relatively small number of dogs".
The five breeds with the highest prevalence of periodontal disease found in the study were the large Greyhound (38.7%), the medium-small Shetland Sheepdog (30.6%), and the extra-small Papillon (29.7%), Toy Poodle (28.9%), and Miniature Poodle (28.2%). Giant breed dogs (such as the Great Dane and Saint Bernard) were among the lowest breed prevalence estimates.
The authors say there are several potential reasons why smaller dogs are more likely to develop dental issues than larger dogs. For example, smaller dogs may have proportionally larger teeth, which can lead to tooth overcrowding and increased build-up of plaque leading to inflammation of gums. Smaller dogs also have less alveolar bone (the bone that contains tooth sockets) compared to their relatively large teeth.
Corrin added: "Regardless of the reasons that smaller dogs have increased risk for periodontal disease, knowing the true magnitude of the risk across breeds is an important step in providing quality care for all dogs, both in the veterinarian’s office and at home.
Under the direction of Hilary Jackson and Rosanna Marsella, the manual has been revised and updated to provide a resource focused on the clinically relevant aspects of dermatological diseases. It also includes several new chapters and various sections have been expanded.
This new edition keeps the same format as the third edition. The initial chapters review the basic structure and function of the skin, discuss a logical approach to history-taking and outline the core investigative tests that can be performed. A separate chapter on skin cytology has been added to this edition, providing information on common skin diseases which the association says should be useful to all practitioners.
The introductory section is followed by chapters taking a problem-oriented approach to common dermatological conditions, including papules and pustules, scaling, and erosions and ulcerations. The chapters on pyoderma, ear disease and atopic dermatitis have been expanded and there are two new chapters dedicated to feline dermatological conditions.
A chapter covering the indications for allergy testing and the use of allergen-specific immunotherapy is also new to this edition. The main purpose of an allergy test is to confirm the clinical diagnosis of atopic disease and to identify the relevant allergens, which can then be selected for allergen-specific immunotherapy.
The final section of the manual focuses on the major skin diseases encountered in dogs and cats, and includes a chapter on topical treatments, which have an increasingly important role in the management of small animal dermatology patients, either as a sole therapy or as part of a multimodal treatment regime.
The BSAVA Manual of Canine and Feline Dermatology is available as a print edition (£90; £60 to BSAVA members), which can be bought at the BSAVA online shop, and a digital edition (£90; £60 to BSAVA members), accessible via the BSAVA Library.
Alasdair qualified from Cambridge in 1990. After graduation, he joined Bristol Vet School, first as an intern and then as a resident. He then became a Lecturer and Senior Clinical Fellow in small animal surgery at Langford from 1997 to 2009. He was also the Programme Director of the veterinary nursing degree and led years 3-5 of the BVSc programme.
He then moved to private practice, becoming Head of Referral Surgery at Bath Vet Referrals, and then Group Veterinary Advisor and member of the Clinical Advisory Board when it was acquired by IVC, after which he moved to Vale Referrals.
He received his Fellowship for Contributions to Clinical Practice in 2017 and is an Advanced Practitioner in Small Animal Surgery.
Alasdair will mainly be helping to develop Brains & Drains, a new library of peer-reviewed clinical demonstrations published on YouTube for the benefit of veterinary professionals around the world. He’ll also be helping to steer the development of other content on VetNurse.co.uk and VetSurgeon.org
Publishing Editor Arlo Guthrie said: “Alasdair and I first collaborated nine years ago to make a film called: Total Ear Canal Ablation and Lateral Bulla Osteotomy. Who’d have that would be such a box office hit, with over 90,000 views on Facebook!
“Now we’re stepping up production, both by filming our own content and inviting all vets and nurses to film demonstrations themselves and submit them for peer review.”
Arlo added: “In recent years, there's been an explosion in the number of social media groups for the veterinary profession, primarily on Facebook and Instagram, which has led to a real fragmentation. It’s as yet unclear whether that'll always be the case. Certainly young people are already migrating elsewhere, both because it’s not very hip to be on the same platform as your parents, and also a growing awareness of some of the harms of Facebook on mental health."
“Either way, with so much fragmentation, it is clear we need to offer more by way of quality content on VetNurse.co.uk than we have in the past, and I’m really excited to be working alongside Alasdair to do just that, so that whatever the ups and downs of other social media, VetNurse and VetSurgeon remain reliable, transparent places for good quality information sharing.”
Louise is an RCVS and EBVS European Specialist in Veterinary Anaesthesia and Analgesia, and a Past President of the Pain Medicine Section Council at the Royal Society of Medicine. She has also been an invited examiner on the European Diploma examination and a Treasurer of the Association of Veterinary Anaesthetists. She has headed the anaesthesia team at Davies since 2007.
Her tips are:
The interviews give an insight into the career advice the interviewees got from their school, what steps they took to secure their place to study for their qualification, what hurdles they had to overcome and what can be done to address issues around the under-representation of some groups within the profession.
The College says the aim is to help inspire school age children to consider a veterinary career through frank conversations with role models who have chosen a vet or vet nursing career.
The first film is an interview with Rheanna Ellis, a 2021 Nottingham Vet School graduate who is now working as a veterinary surgeon at a West Midlands practice. In her interview she talks about her passion to become a vet from a young age, how she went about researching and preparing for her job, and the importance of perseverance.
To help promote the videos and the College’s ongoing work on diversity and inclusion, the RCVS has partnered with the official Black History Month campaign and website which will also be hosting the videos.
Many of the interviews have been carried out by Mandisa Greene, RCVS Senior Vice-President, who helped lead the RCVS Black History Month activities last year as the College’s first ever black President.
Mandisa said: “It’s important that we demonstrate commitment to diversity and inclusion and have a role in acknowledging and accentuating diverse voices within the professions. Throughout these video interviews I’ve had the opportunity to speak to some inspiring newly qualified and student veterinary professionals who are all clearly very passionate about supporting animal health and welfare.
“I hope that school children from all backgrounds who watch these videos will get the chance to see how rewarding and enjoyable a veterinary career can be and that they’ll be inspired to consider becoming a vet or vet nurse in the future.”
The RCVS will be publishing more video interviews on its YouTube channel through October and beyond.
Rob Chapman, MD of the event organiser, CloserStill Media, said: "The London Vet Show in 2019 was the last major in-person event pre-Covid-19 pandemic
“We are delighted to be gathering once more. We had more tickets booked this September than any other year which has reinforced that there’s a real desire amongst the veterinary community to get back together and that confidence in events is returning.
"Our team is busy putting the final touches in place – including our new Covid-safety features, our speakers are excited to present to live audiences again, the delegates are making plans to see old friends. And, very importantly, our exhibitors are busy organising fantastic giveaways and getting stock ready. There has been so much fantastic R&D in the veterinary sector over the past two years and vet professionals will get to try it out first at the London Vet Show.”
BVA Senior Vice President, James Russell, said: “The London Vet Show is a highlight of the CPD and social calendar. The range of lectures we have on means there’s something for everybody – whether it’s clinical, non-clinical, BVA Congress or our career development stream. But the opportunity to see each other again after two years is something which I am so excited about.
"I know that there will be some people feeling nervous about the idea of coming together again. But one of the tremendous privileges I’ve had during the past year is being in London and watching it slowly unlock. I have to say that my recent experiences of being out and about in London make me feel very safe here.
"I do recognise that different people are at different points on their journey with that, but I hope that everyone finds a way of getting to the London Vet Show in a way they feel comfortable with. CloserStill have put in measures when we are there that will make us feel as safe and as comfortable as we can do.”
Professor Jill Maddison, who programmes the Royal Veterinary College Clinical’s small animal streams, said: “After almost two years I am beyond excited that we will be back together again at the London Vet Show. As usual we have a great line up of speakers from abroad, the RVC and around the UK who will deliver lectures covering many different aspects of clinical practice.
"I hope that whatever sessions you attend and whatever exhibits you visit at the 12th LVS you will find something to interest, intrigue and inspire you that you can take back to your practice to enhance the welfare of your patients and clients, your team and of course, yourself.”
Rob added: “We also have some fantastic new and returning features in store for delegates. For example, I’m delighted to announce the return of the popular Community Masterminds where online peers can meet in person and discuss topics that matter most to them.
"We are also hosting our very first Very Happy Hour on the exhibition floor from 5.30-6.45 pm on Day 1 where there will be drinks available for everyone to enjoy in a relaxed, spread-out fashion to celebrate being back together again.”
“We do ask that delegates planning on attending pre-register so we can best lay out the event and cater for the audience in a Covid-secure manner.”
One day and two-day tickets are available now. Register before Friday, 22nd October to receive your badge in the post. You can book at: https://london.vetshow.com/, call +44 (0)2476 719 687.
Colin graduated from the RVC in 1992 and has worked as a clinical veterinary surgeon in a variety of first opinion practices and referral centres. He trained as a veterinary anaesthetist at Bristol and Cambridge Universities before moving into the pharmaceutical industry, gaining experience in drug development and technical support, and pre- and post-marketing, at a number of companies.
Colin said: “Animalcare is introducing a number of new and innovative medicines, such as Daxocox, its weekly NSAID to reduce breakthrough pain in dogs with osteoarthritis, to the veterinary sector. This makes it an exciting environment in which to provide technical support.
“I’m looking forward to exploring how my experience can be most useful in supporting Animalcare’s expansion and, more importantly, ensuring that the company’s customers receive the guidance and advice they need to optimise the effectiveness of Animalcare’s product range in treating their patients.”
For technical support, email: technical@animalcare.co.uk
The virtual walks come in the form of a 30 day series of emails taking owners on an imaginary adventure exploring different environments and looking for the things that make these places so exciting for an arthritic dog. Each email will include soundbites from experts and CAM founder Hannah Capon, together with tips and advice.
This year, the charity is also fundraising to keep its live sessions free, to keep its resources accessible to the public and to refurbish its website for owners and animal health professionals.
There are three levels of participation: Garden Wanderer is £10 and gives access to the emails, Facebook group, discount codes and the chance to win prizes and play Big Walk Bingo. Park Explorer is priced at £40 for which participants also get a CAM big walks T-shirt (ladies or unisex fit) and a dog bandana to match. Finally, the £70 Forest Adventurer package adds access to CAM Comprehensive, a course to help owners on their journey with their arthritic dog.
Hannah said: "Please support us, and invite your dog-owning friends and colleagues to do the same. Share the event to your social media pages and help us get the message out that there is more to life with an arthritic dog and even if a dog can’t do the activities they used to there is still a whole world of fun to be found out there whether it is at the beach, in the local park or simply in the garden!"
For more information, visit: https://www.camonlineshop.com/the-big-walk-2021/
Pockit Central is a benchtop analyser which completes tests in 85 minutes.
The new PCR tests include: Lyme disease, Dirofilaria immitis, Neospora caninum, Pseudomonas aeruginosa, Mec A gene for MRSA, IBR and C. difficile. The system has tests tailored to small animal, equine and farm practice, with specialist assays also available for poultry and aquaculture.
The new additions extend the capabilities of the Pockit to more than 190 assays, testing up to 8 pathogens in one run. Horiba says the Pockit is so easy to set up that a laboratory can be up and running within 30 minutes with staff training provided.
Horiba has also published its recent veterinary CPD webinar in which the value of in-house PCR analysis for pathogen screening is discussed with the Head of ESCCAP (European Scientific Council for Companion Animal Parasites) UK & Ireland, in conjunction with the importance of screening imported dogs: The webinar is available to watch on-demand at: https://www.horiba.com/en_en/veterinary/support/webinars/
Equibactin oral powder comes in a 60g sachet, which Dechra says is the scientifically considered accurate dose1 for two daily treatments for a 600kg horse. The sachets come in a box of 10, which is sufficient for the twice daily treatment of a 600kg horse for five days.
The combination of sulfadiazine and trimethoprim antibiotics (known as TMPS) has a broad spectrum of uses and can be used to treat equine infections associated with Streptococcus and Staphylococcus aureus, gastrointestinal infections associated with E. coli and urogenital infections associated with beta-hemolytic streptococci.
Emma Jennings, Equine and Food Producing Animal Brand Manager, said: “Our product allows for twice daily 30mg/kg treatments, making the treatment of large horses easier and ensuring they receive the correct dose, which is crucial when it comes to tackling antibiotic resistance.”
She added: “TMPS is the only registered oral antibiotic available for use in horses and it is recommended as the first line of treatment for ‘common’ equine bacterial infections including those which have developed through wound infections or open or drained abscesses.2,3
“Effective antibiotics are an important part of the veterinarian’s arsenal when it comes to treating a variety of common bacterial infections in horses. But in recent years, the emergence of drug resistant bacteria has meant that extra precautions must be taken to prevent underdosing - one of the prominent causes of drug resistance.”
Equibactin oral powder is available now in the UK and Ireland. For more information visit www.dechra.co.uk.
NexGard Combo is a systemic isoxazoline-based endectocide designed specifically for cats which contains esafoxolaner, eprinomectin and praziquantel.
The new product provides one month’s protection against fleas and five week's protection against the most common tick on cats, Ixodes ricinus. It also treats the roundworms, Toxocara cati and Toxascaris leonina, hookworms, tapeworms and ear mites, against the last of which Nexgard Combo provides 97.2 to 99.9% efficacy following one treatment1.
NexGard Combo can be used in kittens from eight weeks of age and 0.8 kg in weight, making it suitable for most kittens at first vaccination. It is available in two pack sizes: small, for kittens weighing 0.8 - 2.5kg and large, for adult cats weighing 2.5 - 7.5kg. For cats weighing 7.5kg or over, an appropriate combination of applicators should be used.
Jackie Sterratt, senior brand manager at Boehringer Ingelheim, said: “We’re excited to add to the successful NexGard range and to help vets treat more cats. We know only one in two cats is treated for fleas2 and cats are only wormed on average three times per year3 despite all cats being at risk of fleas and most cats requiring monthly roundworming treatment2, 3, so there is a big opportunity to increase treatment rates and compliance. As the only product on the market to treat fleas, ticks, ear mites, roundworms and tapeworms, NexGard Combo offers a simple solution for cats at risk of multiple parasites."
To support the launch Boehringer has produced a marketing package which includes a kitten support pack, client leaflets, dispensing envelope and parasite risk checker.
For further information, contact your local Boehringer Ingelheim territory manager or phone 01344 746957 (UK) or 01 291 3985 (Ireland).